Bioreducible heparin-based nanogel drug delivery system

Biomaterials

Volumn 39, Issue , 2015, Pages 260-268

  Wu, Wei ^a   Yao, Wei ^a   Wang, Xin ^a   Xie, Chen ^a   Zhang, Jialiang ^a   Jiang, Xiqun ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

Antitumor; Doxorubicin; Heparin; Nanogel

Indexed keywords

DRUG DELIVERY; DRUG PRODUCTS; POLYSACCHARIDES; TUMORS;

ANTI-TUMOR ACTIVITIES; ANTI-TUMORS; CONCENTRATION MEASUREMENT; DOXORUBICIN; FLUORESCENCE IMAGING; HEPARIN; HYDRODYNAMIC DIAMETER; NANOGELS;

NANOSTRUCTURED MATERIALS;

DOXORUBICIN; HEPARIN; NANOMATERIAL; DOXORUBICIN-HEPARIN; MACROGOL DERIVATIVE; NANOGEL; POLYETHYLENEIMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER LOCALIZATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG RELEASE; EX VIVO STUDY; HYDRODYNAMICS; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; ANIMAL; CHEMISTRY; HUMAN; LIVER NEOPLASMS; MALE; PROCEDURES; TUMOR CELL LINE;

MUS;

ANIMALS; CELL LINE, TUMOR; DOXORUBICIN; DRUG DELIVERY SYSTEMS; HEPARIN; HUMANS; LIVER NEOPLASMS; MALE; MICE; POLYETHYLENE GLYCOLS; POLYETHYLENEIMINE;

EID: 84919497610     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.11.005     Document Type: Article

References (27)

1. Chacko R.T., Ventura J., Zhuang J.M., Thayumanavan S. Polymer nanogels: a versatile nanoscopic drug delivery platform. Adv Drug Delivery Rev 2012, 64:836-851.
2. Fleige E., Quadir M.A., Haag R. Stimuli-responsive polymeric nanocarriers for the controlled transport of active compounds: concepts and applications. Adv Drug Delivery Rev 2012, 64:866-884.
3. de la Rica R., Aili D., Stevens M.M. Enzyme-responsive nanoparticles for drug release and diagnostics. Adv Drug Delivery Rev 2012, 64:967-978.
4. Nelson D.L., Cox M.M. Lehninger, principles of biochemistry 2008, 251. W. H. Freeman and Company, New York.
5. Lee K.W., Yoon J.J., Lee J.H., Kim S.Y., Jung H.J., Kim S.J., et al. Sustained release of vascular endothelial growth factor from calcium-induced alginate hydrogels reinforced by HEP and chitosan. Transpl Proc 2004, 36:2464-2465.
6. Borsig L., Wong R., Hynes R.O., Varki N.M., Varki A. Synergistic effects of l- and p-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis. Proc Natl Acad Sci U S A 2002, 99:2193-2198.
7. Varki N.M., Varki A. HEP inhibition of selectin-mediated interactions during the hematogenous phase of carcinoma metastasis: rationale for clinical studies in humans. Semin Thromb Hemost 2002, 28:53-66.
8. Freeman C., Browne A.M., Parish C.R. Evidence that platelet and tumour heparanases are similar enzymes. Biochem J 1999, 342:361-368.
9. Wang X., Li J., Wang Y., Koenig L., Gjyrezi A., Giannakakou P., et al. Afolate receptor-targeting nanoparticle minimizes drug resistance in a human cancer model. ACS Nano 2011, 5:6184-6194.
10. Park K., Kim K., Kwon I.C., Kim S.K., Lee S., Lee D.Y., et al. Preparation and characterization of self-assembled nanoparticles of HEP-deoxycholic acid conjugates. Langmuir 2004, 20:11726-11731.
11. Park K., Lee G.Y., Kim Y.S., Yu M., Park R.W., Kim I.S., et al. HEP-DOCA acid chemical conjugate as an anti-cancer drug carrier and its anti-tumor activity. JControl Release 2006, 114:300-306.
12. Park K., Lee G.Y., Park R.W., Kim I.S., Kim S.Y., Byun Y., et al. Combination therapy of HEP-deoxycholic acid conjugate and doxorubicin against squamous cell carcinoma and B16F10 melanoma. Pharm Res 2008, 25:268-276.
13. Hou L., Yao J., Zhou J., Zhang Q. Pharmacokinetics of a paclitaxel-loaded low molecular weight HEP-all-trans-retinoid acid conjugate ternary nanoparticulate drug delivery system. Biomaterials 2012, 33:5431-5440.
14. Park K., Kim Y.S., Lee G.Y., Park R.W., Kim I.S., Kim S.Y., et al. Tumor endothelial cell targeted cyclic RGD-modified HEP derivative: inhibition of angiogenesis and tumor growth. Pharm Res 2008, 25:2786-2798.
15. Wang X., Li J., Wang Y., Cho K.J., Kim G., Gjyrezi A., et al. HFT-T, a targeting nanoparticle, enhances specific delivery of paclitaxel to folate receptor-positive tumors. ACS Nano 2009, 3:3165-3174.
16. Bae H.K., Mok H., Park T.G. Synthesis, characterization, and intracellular delivery of reducible HEP nanogels for apoptotic cell death. Biomaterials 2008, 29:3376-3383.
17. Raina S., Missiakas D. Making and breaking disulfide bonds. Annu Rev Microbiol 1997, 51:179-202.
18. Kuppusamy P., Li H., Ilangovan G., Cardounel A.J., Zweier J.L., Yamada K., et al. Noninvasive imaging of tumor redox status and its modification by tissue glutathione levels. Cancer Res 2002, 62:307-312.
19. Sun Y., Yan X., Yuan T., Liang J., Fan Y., Gu Z., et al. Disassemblable micelles based on reduction-degradable amphiphilic graft copolymers for intracellular delivery of doxorubicin. Biomaterials 2010, 31:7124-7131.
20. Kim D., Gao Z.G., Lee E.S., Bae Y.H. Invivo evaluation of doxorubicin-loaded polymeric micelles targeting folate receptors and early endosomal pH in drug-resistant ovarian cancer. Mol Pharm 2009, 6:1353-1362.
21. Rytting E., Bur M., Cartier R., Bouyssou T., Wang X., Krüger M., et al. Invitro and invivo performance of biocompatible negatively-charged salbutamol-loaded nanoparticles. JControl Rel 2010, 141:101-107.
22. Qian H., Wang X., Yuan K., Xie C., Wu W., Jiang X., et al. Delivery of doxorubicin invitro and invivo using bio-reductive cellulose nanogels. Biomater Sci 2014, 2:220-232.
23. Cheng Y., Yu S., Zhen X., Wang X., Wu W., Jiang X. Alginic acid nanoparticles prepared through counterion complexation method as a drug delivery system. ACS Appl Mater Interfaces 2012, 4:5325-5332.
24. Bae K.H., Mok H., Park T.G. Synthesis, characterization, and intracellular delivery of reducible HEP nanogels for apoptotic cell death. Biomaterials 2008, 29:3376-3383.
25. Saito G., Swanson J.A., Lee K.-D. Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. Adv Drug Delivery Rev 2003, 55:199-215.
26. Gupte A., Mumper R.J. Elevated copper and oxidative stress in cancer cells as a target for cancer treatment. Cancer Treat Rev 2009, 35:32-46.
27. Cheng Y., Yu S., Wang J., Qian H., Wu W., Jiang X. Invitro and invivo antitumor activity of doxorubicin-loaded aliginic-acid-based nanoparticles. Macromol Biosci 2012, 12:1326-1335.